Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-BX200
- Development stage
- Preclinical
- Lead developer
- Neurocarrus
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Subcutaneous, Intradermal
01
Overview
N-BX200 is an engineered recombinant protein biologic being developed by Neurocarrus. It is designed for indications typically addressed by botulinum toxin (Botox), which include a wide range of aesthetic and therapeutic applications such as the treatment of glabellar lines, muscle spasticity, hyperhidrosis, and chronic migraine. As a recombinant protein, N-BX200 is part of a new generation of neurotoxin-based therapies engineered to potentially offer improved purity, stability, or modified pharmacokinetics compared to traditional tissue-derived botulinum toxin products. The asset is currently in early-stage development as part of Neurocarrus's pipeline of targeted biologics for neuromuscular and aesthetic medicine.
Beyond the preview
Go deeper on N-BX200.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on N-BX200.